BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31582465)

  • 1. International Anemia Prevalence and Management in Peritoneal Dialysis Patients.
    Perlman RL; Zhao J; Fuller DS; Bieber B; Li Y; Pisoni RL; Robinson BM; Johnson DW; Kawanishi H; Davies SJ; Schreiber MJ; Perl J
    Perit Dial Int; 2019; 39(6):539-546. PubMed ID: 31582465
    [No Abstract]   [Full Text] [Related]  

  • 2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UK Renal Registry 16th annual report: chapter 10 haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2012: national and centre-specific analyses.
    Rao A; Gilg J; Williams A
    Nephron Clin Pract; 2013; 125(1-4):183-208. PubMed ID: 24662174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chapter 8 Haemoglobin, ferritin and erythropoietin amongst UK adult dialysis patients in 2010: national and centre-specific analyses.
    Webb L; Gilg J; Wilkie M
    Nephron Clin Pract; 2012; 120 Suppl 1():c145-74. PubMed ID: 22964566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia in patients undergoing ambulatory peritoneal dialysis: prevalence and associated factors.
    Oliveira MC; Ammirati AL; Andreolli MC; Nadalleto MA; Barros CB; Canziani ME
    J Bras Nefrol; 2016 Mar; 38(1):76-81. PubMed ID: 27049368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemoglobin stability and patient compliance with darbepoetin alfa in peritoneal dialysis patients after the implementation of the prospective payment system.
    Pirkle JL; Paoli CJ; Russell G; Petersen J; Burkart J
    Clin Ther; 2014 Nov; 36(11):1665-74. PubMed ID: 25256386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
    Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
    Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis.
    Perl J; Davies SJ; Lambie M; Pisoni RL; McCullough K; Johnson DW; Sloand JA; Prichard S; Kawanishi H; Tentori F; Robinson BM
    Perit Dial Int; 2016; 36(3):297-307. PubMed ID: 26526049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Robinson BM; Locatelli F; Pisoni RL
    Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients.
    Mitsopoulos E; Lysitska A; Pateinakis P; Lamprou V; Intzevidou E; Minasidis I; Katsaounou C; Kougioumtzidou O; Anagnostou N; Lemonidis N; Papadopoulou D
    Int Urol Nephrol; 2020 Feb; 52(2):387-392. PubMed ID: 31894555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
    Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
    Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Pisoni RL; Bragg-Gresham JL; Young EW; Akizawa T; Asano Y; Locatelli F; Bommer J; Cruz JM; Kerr PG; Mendelssohn DC; Held PJ; Port FK
    Am J Kidney Dis; 2004 Jul; 44(1):94-111. PubMed ID: 15211443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis.
    Ryta A; Chmielewski M; Debska-Slizien A; Jagodzinski P; Sikorska-Wisniewska M; Lichodziejewska-Niemierko M
    Int Urol Nephrol; 2017 May; 49(5):903-908. PubMed ID: 28058668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International comparison of peritoneal dialysis prescriptions from the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).
    Wang AY; Zhao J; Bieber B; Kanjanabuch T; Wilkie M; Marshall MR; Kawanishi H; Perl J; Davies S;
    Perit Dial Int; 2020 May; 40(3):310-319. PubMed ID: 32063209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.
    Karaboyas A; Zee J; Morgenstern H; Nolen JG; Hakim R; Kalantar-Zadeh K; Zager P; Pisoni RL; Port FK; Robinson BM
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1814-21. PubMed ID: 26286925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron.
    Kapoian T
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S21-8. PubMed ID: 19010258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic outcomes in Medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy.
    Knight TG; Ryan K; Schaefer CP; D'Sylva L; Durden ED
    J Manag Care Pharm; 2010 Oct; 16(8):605-15. PubMed ID: 20866165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.